Klingenberg, Claus; Mouslet, George; Hjalgrim, Helle; Gerstner, Thorsten (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-07-24)
<i>Objectives</i>: There is an increasing interest in cannabinoid-based products for the treatment of refractory pediatric epilepsy. However, a licensed cannabidiol (CBD) product was first approved for use by the European regulatory authorities in 2019. We aimed to obtain knowledge about clinical experience and attitudes toward cannabinoid use for epilepsy treatment among neuropediatricians in ...